Jimin Health: Currently, the stock price trend is significantly diverging from the operating performance trend.

Jin10 data reported on September 11th, Jimin Health issued an abnormality announcement, the company's stock closed at the limit rise again today, with a turnover rate of 16.96%. From September 8 to 11, 2025, the cumulative rise in closing price reached 33.78%. The cumulative deviation of the rise over the past 30 trading days from the Shanghai A-share index is 94.72%. The actual rise and fall fluctuation after excluding the overall factors of the market and zone is quite large, with multiple trading days experiencing continuous big pump and big dump. There are significant anomalies in stock trading, and there may be a risk of rapid fall at any time in the future. The net profit attributable to the parent company's owners for the fiscal year 2024 is -59.7117 million yuan; for the first half of 2025, the company achieved a net profit attributable to the parent company's owners of -52.6959 million yuan. The company's performance is in a loss state, the main business has not changed, and the current stock price trend is significantly deviating from the operating performance trend.